CHSN
Chanson International Holding
There isn't enough reported data to score CHSN yet.
NKE
NIKE, Inc.
NKE's fundamentals are mixed, but it looks cheap: trading at 18x earnings, below its usual 33x. Analysts expect earnings to hold roughly steady, though they disagree widely on how much.
CHSN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Strong |
CHSN's profitability and balance sheet are currently strong. There isn't enough data to rate its revenue and cash flow.
NKE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
NKE's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
CHSN PE Valuation
CHSN has no meaningful PE right now: it lost money over the past year.
NKE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $37.76 | — |
| Cheap | 23x | $47.70 | +26% |
| Forward | 30x | $37.76 | — |
| Fair | 33x | $68.16 | +80% |
| Expensive | 47x | $97.86 | +159% |
Historical ranges are pointers, not guarantees.
NKE's PE is in its cheap range at 18x. On analysts' estimates for next year's earnings, today's price would be 30x, in its fair range.
CHSN Forward outlook
There aren't enough analyst estimates for CHSN to show an outlook.
NKE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Stable | |
| Decline | |
| Improving | |
| Moderate | |
| Low |
Analysts expect NKE's profitability to improve, but its revenue to decline. However, they disagree widely on these estimates.
CHSN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | $400.00 | +1567% |
CHSN and NKE do not have enough comparable growth data to identify a winner.
NKE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.27 | -39% |
| Q3 2026 | $2.09 | +7.2% |
| Q2 2026 | $2.10 | -2.8% |
| Q1 2026 | $1.51 | -50% |
| Q4 2025 | $1.70 | -48% |
| Q3 2025 | $1.95 | -44% |
| Q2 2025 | $2.16 | -42% |
| Q1 2025 | $3.01 | -11% |
| Q4 2024 | $3.24 | -5.3% |
NKE's earnings per share have fallen from their peak: $2.09 over the past year, against $3.82 in late 2021.
CHSN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.3M | -4.5% |
| Q4 2025 | $9.6M | -10% |
| Q2 2025 | $8.7M | +15% |
| Q4 2024 | $10.7M | +27% |
| Q2 2024 | $7.5M | -14% |
| Q4 2023 | $8.4M | +79% |
| Q2 2023 | $8.8M | +3.1% |
| Q4 2022 | $4.7M | -41% |
CHSN has the edge over NKE in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -9.4% | -2 points |
| Q4 2025 | -7.3% | +1.3 points |
| Q2 2025 | -14% | -15 points |
| Q4 2024 | 0.3% | +32 points |
| Q2 2024 | -7.4% | -6.9 points |
| Q4 2023 | -8.6% | -4.6 points |
| Q2 2023 | 1.3% | +5.3 points |
| Q4 2022 | -32% | -20 points |
CHSN's operating margin was −9.4% last quarter, down 2 points from the same quarter a year ago.
NKE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.2B | -4.3% |
| Q2 2026 | $11B | -1.1% |
| Q1 2026 | $11.3B | +0.1% |
| Q4 2025 | $12.4B | +0.6% |
| Q3 2025 | $11.7B | +1.1% |
| Q2 2025 | $11.1B | -12% |
| Q1 2025 | $11.3B | -9.3% |
| Q4 2024 | $12.4B | -7.7% |
NKE's revenue fell from its 2023 peak and has held roughly level since: $11.2B last quarter, down 4.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.2% | +0.3 points |
| Q2 2026 | 12% | +9.2 points |
| Q1 2026 | 5.8% | -1.7 points |
| Q4 2025 | 8% | -3.4 points |
| Q3 2025 | 7.9% | -3.4 points |
| Q2 2025 | 2.9% | -11 points |
| Q1 2025 | 7.5% | -3.8 points |
| Q4 2024 | 11% | -2.9 points |
NKE has the edge over CHSN on profitability, with a higher operating margin.
CHSN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | $2.2M | +$6.4M |
| Q2 2024 | $771.9K | +68% |
| Q4 2023 | -$4.2M | -778% |
| Q2 2023 | $458.1K | +$1.4M |
| Q4 2022 | $617.7K | +$1M |
| Q2 2022 | -$926.4K | -738% |
| Q4 2021 | -$405.1K | -164% |
| Q2 2021 | $145.3K | +263% |
CHSN's free cash flow was −$4M over the past year, against −$255,670 the year before.
NKE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$64M | -527% |
| Q2 2026 | $1.5B | +313% |
| Q1 2026 | $284M | -83% |
| Q4 2025 | $386M | -58% |
| Q3 2025 | $15M | -95% |
| Q2 2025 | $363M | -85% |
| Q1 2025 | $1.7B | -11% |
| Q4 2024 | $920M | -65% |
NKE usually generates cash, though not every quarter: the latest was −$64M, but it generated $2.1B over the past year.
CHSN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +85094% | +1.3M shares |
| 1 year | +730% | +1.2M shares |
CHSN has 1M diluted shares, up 730% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2022 | — |
| Q2 2022 | — |
| Q4 2021 | — |
| Q2 2021 | — |
| Q4 2020 | — |
| Q2 2020 | — |
| Q4 2019 | — |
NKE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +3.2M shares |
| 1 year | +0.4% | +5.2M shares |
| 3 years | -3.8% | -59.1M shares |
| 5 years | -8.4% | -135M shares |
| Available history | -6.9% | -110M shares |
NKE has the edge over CHSN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $20M |
| Q3 2025 | $126M |
| Q2 2025 | $199M |
| Q1 2025 | $506M |
| Q4 2024 | $1.1B |
NKE has spent almost nothing on buybacks in the past year.
CHSN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | -36.0x | Net Cash |
CHSN has more cash than debt.
NKE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.2x | Very low |
| Q2 2026 | 0.1x | Very low |
| Q1 2025 | 0.1x | Very low |
| Q4 2024 | 0.2x | Very low |
| Q3 2024 | 0.1x | Very low |
| Q2 2024 | -0.1x | Net Cash |
| Q1 2024 | -0.0x | Very low |
| Q4 2023 | 0.1x | Very low |
NKE's net debt is less than a year of its operating earnings (EBITDA).
CHSN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.6 | Neutral |
| Stochastic | 35.1 | Neutral |
CHSN's weekly RSI is 33 (neutral) and its Stochastic is 35 (neutral).
NKE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.0 | Neutral |
| Stochastic | 57.5 | Neutral |
NKE's weekly RSI is 40 (neutral) and its Stochastic is 58 (neutral).
CHSN PE vs Consumer Cyclical Sector
| Metric | CHSN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
CHSN has no meaningful PE right now: it lost money over the past year.
NKE PE vs Consumer Cyclical Sector
| Metric | NKE | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 18x | 0.3% above |
| PE % | 2 | 47 | 45 pts below |
NKE is trading at 18x earnings, in line with the Consumer Cyclical sector's median of 18x.
CHSN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.25 | 52% below |
| 20 week MA | $1.15 | 48% below |
| 50 week MA | $92.1 | 99% below |
| 100 week MA | $3,017.9 | 100% below |
NKE has stronger trend alignment. CHSN is above 0 of 4 weekly averages versus NKE above 1 of 5.
NKE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.7 | 2.8% above |
| 20 week MA | $39.2 | 3.6% below |
| 50 week MA | $48.0 | 21% below |
| 100 week MA | $58.4 | 35% below |
| 200 week MA | $79.2 | 52% below |
NKE has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 52% below its 200-week average.
CHSN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $16,880.0 | $9,760.0 | -42% |
| 2024 | $9,760.0 | $46,320.0 | +375% |
| 2025 | $46,320.0 | $209.0 | -100% |
| 2026 YTD | $209.0 | $0.60 | -100% |
CHSN's yearly returns have swung widely, from +375% in 2024 to −100% in 2025. It's down 100% so far in 2026.
NKE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $101.6 | $141.6 | +39% |
| 2021 | $141.6 | $165.7 | +17% |
| 2022 | $165.7 | $116.3 | -30% |
| 2023 | $116.3 | $108.6 | -6.6% |
| 2024 | $108.6 | $76.4 | -30% |
| 2025 | $76.4 | $60.9 | -20% |
| 2026 YTD | $60.9 | $37.8 | -38% |
NKE has the edge over CHSN on returns for 2026, with the stronger performance.